Back to User profile » Dr Yi-Long Wu

Papers published by Dr Yi-Long Wu:

Original Research

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with EGFR-Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program

Tu HY, Wu YL

OncoTargets and Therapy 2020, 13:12539-12547

Published Date: 7 December 2020

Original Research

Familial association of lung cancer with liver cancer in first-degree relatives

Xu CR, Lin H, Su J, Zhang XC, Huang YS, Yang XN, Zhou Q, Yang JJ, Zhong WZ, Wu YL

Cancer Management and Research 2019, 11:5813-5819

Published Date: 28 June 2019

Original Research

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial

Wu YL, Xu CR, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Märten A, Fan J, Peil B, Zhou C

OncoTargets and Therapy 2018, 11:8575-8587

Published Date: 30 November 2018

Review

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib

Niu FY, Wu YL

OncoTargets and Therapy 2015, 8:999-1007

Published Date: 2 May 2015

Review

Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China

Gou LY, Wu YL

Lung Cancer: Targets and Therapy 2014, 5:1-9

Published Date: 12 February 2014